FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes

Ujas Parikh; Charles Marcus; Rutuparna Sarangi; Mehdi Taghipour; Rathan M. Subramaniam

doi:10.1016/j.cpet.2015.03.001

FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes

Ujas Parikh, Charles Marcus, Rutuparna Sarangi, Mehdi Taghipour, Rathan M. Subramaniam

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

Fludeoxyglucose F 18 (¹⁸F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of ¹⁸F-FDG PET/CT in initial staging and patient prognosis. There is evidence for ¹⁸F-FDG PET and ¹⁸F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. ¹⁸F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of ¹⁸F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

Original language	English (US)
Pages (from-to)	327-343
Number of pages	17
Journal	PET Clinics
Volume	10
Issue number	3
DOIs	https://doi.org/10.1016/j.cpet.2015.03.001
State	Published - Jul 1 2015

Keywords

F-FDG PET/CT
Hepatocellular carcinoma
Pancreatic cancer

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2015.03.001

Cite this

@article{597c8da87e134615b33236326ee76e8e,

title = "FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes",

abstract = "Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.",

keywords = "F-FDG PET/CT, Hepatocellular carcinoma, Pancreatic cancer",

author = "Ujas Parikh and Charles Marcus and Rutuparna Sarangi and Mehdi Taghipour and Subramaniam, {Rathan M.}",

year = "2015",

month = jul,

day = "1",

doi = "10.1016/j.cpet.2015.03.001",

language = "English (US)",

volume = "10",

pages = "327--343",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - FDG PET/CT in pancreatic and hepatobiliary carcinomas

T2 - Value to patient management and patient outcomes

AU - Parikh, Ujas

AU - Marcus, Charles

AU - Sarangi, Rutuparna

AU - Taghipour, Mehdi

AU - Subramaniam, Rathan M.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

AB - Fludeoxyglucose F 18 (18F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of 18F-FDG PET/CT in initial staging and patient prognosis. There is evidence for 18F-FDG PET and 18F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. 18F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of 18F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

KW - F-FDG PET/CT

KW - Hepatocellular carcinoma

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84931957361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931957361&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2015.03.001

DO - 10.1016/j.cpet.2015.03.001

M3 - Review article

C2 - 26099670

AN - SCOPUS:84931957361

SN - 1556-8598

VL - 10

SP - 327

EP - 343

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -

FDG PET/CT in pancreatic and hepatobiliary carcinomas: Value to patient management and patient outcomes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this